US FDA considers changes to GLP rules for non-clinical laboratory studies
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration is considering amendments to good laboratory practice (GLP) regulations for sites that conduct non-clinical studies to support applications for research or marketing permits of drugs, medical devices and other regulated products1.